Better coordination between hospitals and post-acute care facilities could reduce patient readmission to hospitals and mortality rates, according to a new study of risk factors by researchers from the University of Colorado ...
Jan 15, 2016
0
2
For half a century, cancer researchers have struggled with a confusing paradox: If cancer is caused by the occurrence and accumulation of cancer-causing (oncogenic) mutations over time, young children should get less cancer ...
Jan 11, 2016
0
15
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent ...
Jan 11, 2016
0
1
A newly NIH funded clinical trial (NCT02528942) by University of Colorado Cancer Center investigators and collaborators at Beaumont Health in Michigan and the University of Texas Medical Branch is evaluating a new method ...
Jan 6, 2016
0
0
How will Medicaid expansion under the Affordable Care Act (ACA) change cancer survivors' access to healthcare? Answering the question first requires defining access to healthcare before the ACA. An analysis published in the ...
Dec 22, 2015
0
0
Despite popular perceptions, cheerleading is one of the safest high school sports, yet the relatively few injuries sustained are often some of the most severe, according to a new study from the Colorado School of Public Health ...
Dec 10, 2015
0
23
Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against ...
Dec 9, 2015
0
121
An ongoing phase IIR/III clinical trial presented at the 2015 San Antonio Breast Cancer Symposium seeks to answer an important question in the treatment of early metastatic breast cancer: Should surgery or stereotactic body ...
Dec 8, 2015
0
36
Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients ...
Dec 7, 2015
0
0
In 1048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, ...
Dec 3, 2015
0
0
